AtriCure (NASDAQ:ATRC) Hits New 1-Year High – Still a Buy?

AtriCure, Inc. (NASDAQ:ATRC)’s stock price reached a new 52-week high during trading on Tuesday . The company traded as high as $55.72 and last traded at $52.3660, with a volume of 238397 shares traded. The stock had previously closed at $51.52.

Wall Street Analyst Weigh In

A number of research firms recently commented on ATRC. BTIG Research lifted their target price on shares of AtriCure from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Monday, August 24th. Needham & Company LLC raised their price target on shares of AtriCure from $45.00 to $64.00 and gave the stock a “buy” rating in a report on Wednesday, September 2nd. Zacks Research downgraded shares of AtriCure from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 24th. Raymond James Financial set a $52.00 price objective on shares of AtriCure in a report on Tuesday, July 21st. Finally, Piper Sandler upped their target price on AtriCure from $50.00 to $60.00 and gave the company an “overweight” rating in a research report on Thursday, August 27th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $52.00.

AtriCure Stock Performance

The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14. The stock has a market capitalization of $2.65 billion, a PE ratio of 249.49 and a beta of 1.26. The firm’s fifty day moving average price is $40.56 and its two-hundred day moving average price is $32.96.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The business had revenue of $153.60 million during the quarter, compared to analysts’ expectations of $151.80 million. During the same period last year, the business earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, equities research analysts forecast that AtriCure, Inc. will post 0.29 EPS for the current year.

Insider Buying and Selling at AtriCure

In other news, Director Maggie Yuen sold 3,500 shares of the firm’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $38.42, for a total value of $134,470.00. Following the transaction, the director owned 14,015 shares of the company’s stock, valued at approximately $538,456.30. This trade represents a 19.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Karl S. Dahlquist sold 9,370 shares of AtriCure stock in a transaction on Monday, August 24th. The shares were sold at an average price of $48.89, for a total transaction of $458,099.30. Following the transaction, the insider owned 87,319 shares in the company, valued at $4,269,025.91. The trade was a 9.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 61,379 shares of company stock worth $2,557,552. 4.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ATRC. Bank of America Corp DE boosted its position in shares of AtriCure by 13.7% in the first quarter. Bank of America Corp DE now owns 768,561 shares of the medical device company’s stock worth $21,927,000 after buying an additional 92,830 shares during the period. Man Group plc acquired a new position in AtriCure during the 2nd quarter worth approximately $684,000. Assenagon Asset Management S.A. acquired a new position in AtriCure during the 2nd quarter worth approximately $1,744,000. Rice Hall James & Associates LLC purchased a new position in AtriCure in the 2nd quarter worth approximately $3,755,000. Finally, Vanguard Group Inc. grew its position in AtriCure by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 4,903,755 shares of the medical device company’s stock valued at $193,993,000 after acquiring an additional 62,861 shares in the last quarter. 99.11% of the stock is owned by hedge funds and other institutional investors.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.